| HOME >> MEDICINE >> TECHNOLOGY |
-- F1-337: In Vivo Efficacy of Rx100472, A Novel Methionyl-tRNA Synthetase
(MetRS) Inhibitor
Sunday, October 26th
(Poster Session 92, 11:15 am - 12:15 pm)
-- A-985: Pharmacodynamics of TR-701 in a Mouse Thigh Infection Model
Against S. aureus ATCC 33591, a Methicillin-Resistant Isolate
Monday, October 27th
(Poster Session 196, 11:15 am - 12:15 pm)
-- F1-2060: MICs of TR-700, the Active Moiety of the Novel Oxazolidinone
Prodrug TR-701, for Linezolid-Susceptible and - Resistant Enterococci
and Staphylcocci
-- F1-2061: TR-700, a Novel Oxazolidinone, Tested Against
Linezolid-Resistant Gram-Positive Species with Well-Characterized
Resistance Mechanisms
-- F1-2062: In Vitro Pharmacodynamics of TR-700, the Active Moiety of
Prodrug TR-701, a Novel Oxazolidinone, in a Kill-Curve Model
-- F1-2063: Human Pharmacokinetics of TR-700 after Ascending Single Oral
Doses of the Prodrug TR-701, a Novel Oxazolidinone Antibiotic
-- F1-2064: Human Pharmacokinetics of TR-700 after Multiple Oral Doses of
200 and 400 mg of TR-701, a Novel Oxazolidinone Antibiotic
-- F1-2065: In Vitro and In Vivo Efficacy of TR-701 and TR-700 Versus the
Linezolid- and Methicillin-Resistant Staphylococcus aureus cfr Strain
CM/05
-- F1-2066: Demonstration of TR-701 Efficacy in a Mouse Inhalation Anthrax
Model
-- F1-2067: Absence of a Pressor Response to Oral Tyramine in Conscious
Telemeterized Rats Treated with the Novel Oxazolidinone TR-701:
Comparison to Linezolid
-- F1-2068: Quality Control Parameters for TR-700 Broth Microdilution
Susceptibility Tests
-- F1-2069: Relative Potency of TR-700, the Active Moiety of Prodrug
TR-701, Against Selected Bacterial Pathogens and Provisional Disk Test
Criteria
-- F1-2
'/>"/>
| SOURCE Trius Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |